Profile of:

Fabiola Atzeni


Fabiola Atzeni, MD, PhD is currently Full Professor and Head of Rheumatology Unit, in the University of Messina, Messina, Italy. Her clinical and research interest lies in immunotherapies in autoimmune diseases with particular focus on the investigation and management of differential response to biological therapies in rheumatoid arthritis (RA) and Spondyloarthritis (SpA), and cardiovascular aspects of the different rheumatic diseases with particular emphasis on arteriosclerosis. Dr. Atzeni has (co)authored over 460 publications in peer-reviewed journals and several book chapters, is a regular reviewer for several international journals. She is involved in several (international/national) meetings focused on cardiovascular and infection aspects in rheumatic disease.

Full name: Fabiola Atzeni

Current country: Italy

Membership level: Full

Type of membership: Member

Number of publications: 14

Early Spondyloarthritis Clinic: Organizational Improvements in the Patient Journey (2022)
https://pubmed.ncbi.nlm.nih.gov/35685409/

IL-23 in axial spondyloarthritis and psoriatic arthritis: a good fit for biological treatment? (2022)
https://pubmed.ncbi.nlm.nih.gov/35722768/

Axial Spondyloarthritis: Reshape the Future-From the “2022 GISEA International Symposium” (2022)
https://pubmed.ncbi.nlm.nih.gov/36556152/

Anti-IL-17 Agents in the Treatment of Axial Spondyloarthritis (2021)
https://pubmed.ncbi.nlm.nih.gov/33977094/

Study of entheses in patients with spondyloarthritis and inflammatory bowel disease with and without fibromyalgia: The importance of ultrasonography. Atzeni F, Sciortino D, Nucera V, Fries W, Sarzi-Puttini P, Salaffi F, Galloway J, Bonitta G. (2020)
https://pubmed.ncbi.nlm.nih.gov/?term=atzeni+f+spondyloarthritis&format=pmid&sort=pubdate

Cardiovascular risk in ankylosing spondylitis and the effect of anti-TNF drugs: a narrative review. Atzeni F, Nucera V, Galloway J, Zoltán S, Nurmohamed M. Expert Opin Biol Ther. 2020 May;20(5):517-524 (2020)
https://pubmed.ncbi.nlm.nih.gov/?term=atzeni+f+spondyloarthritis&format=pmid&sort=pubdate

Study of entheses in patients with spondyloarthritis and inflammatory bowel disease with and without fibromyalgia: The importance of ultrasonography. Atzeni F, Sciortino D, Nucera V, Fries W, Sarzi-Puttini P, Salaffi F, Galloway J, Bonitta G. Joint Bone Spine. 2020 Oct;87(5):507-508. (2020)
https://pubmed.ncbi.nlm.nih.gov/?term=atzeni+f+spondyloarthritis&format=pmid&sort=pubdate

AxSpA patients who also meet criteria for fibromyalgia: identifying distinct patient clusters using data from a UK national register (BSRBR-AS). Macfarlane GJ, Pathan E, Siebert S, Packham J, Gaffney K, Choy E, Sengupta R, Atzeni F, Martin KR, Jones GT, Dean LE. BMC Rheumatol. 2019 May 20;3:19. (2019)
https://pubmed.ncbi.nlm.nih.gov/?term=atzeni+f+spondyloarthritis&format=pmid&sort=pubdate

Rate of serious infections in spondyloarthropathy patients treated with anti-tumour necrosis factor drugs: a survey from the Italian registry GISEA. Atzeni F, Sarzi-Puttini P, Sebastiani M, Panetta V, Salaffi F, Iannone F, Carletto A, Foti R, Gremese E, Govoni M, Marchesoni A, Favalli E, Gorla R, Ramonda R, Ferraccioli G, Lapadula G; GISEA group.. Clin Exp Rheumatol. 2019 Jul-Aug;37(4):649-655 (2019)
https://pubmed.ncbi.nlm.nih.gov/?term=atzeni+f+spondyloarthritis&format=pmid&sort=pubdate

Influence of co-morbid fibromyalgia on disease activity measures and response to tumour necrosis factor inhibitors in axial spondyloarthritis: results from a UK national register. Macfarlane GJ, MacDonald RIR, Pathan E, Siebert S, Gaffney K, Choy E, Packham J, Martin KR, Haywood K, Sengupta R, Atzeni F, Jones GT. Rheumatology (Oxford). 2018 Nov 1;57(11):1982-1990. (2018)
https://pubmed.ncbi.nlm.nih.gov/?term=atzeni+f+spondyloarthritis&format=pmid&sort=pubdate

Incidence of cancer in patients with spondyloarthritis treated with anti-TNF drugs. Atzeni F, Carletto A, Foti R, Sebastiani M, Panetta V, Salaffi F, Bonitta G, Iannone F, Gremese E, Govoni M, Marchesoni A, Favalli EG, Gorla R, Ramonda R, Sarzi-Puttini P, Ferraccioli G, Lapadula G; GISEA group. Joint Bone Spine. 2018 Jul;85(4):455-459. (2018)
https://pubmed.ncbi.nlm.nih.gov/?term=atzeni+f+spondyloarthritis&format=pmid&sort=pubdate

Ankylosing Spondylitis Treatment after First Anti-TNF Drug Failure. Benucci M, Damiani A, Bandinelli F, Grossi V, Infantino M, Manfredi M, Gobbi FL, Sarzi-Puttini P, Atzeni F. Isr Med Assoc J. 2018 Feb;20(2):119-122. (2018)
https://pubmed.ncbi.nlm.nih.gov/?term=atzeni+f+spondyloarthritis&format=pmid&sort=pubdate

Co-Occurrence and Characteristics of Patients With Axial Spondyloarthritis Who Meet Criteria for Fibromyalgia: Results From a UK National Register. Macfarlane GJ, Barnish MS, Pathan E, Martin KR, Haywood KL, Siebert S, Packham J, Atzeni F, Jones GT. Arthritis Rheumatol. 2017 Nov;69(11):2144-2150 (2017)
https://pubmed.ncbi.nlm.nih.gov/?term=atzeni+f+spondyloarthritis&format=pmid&sort=pubdate

Disease Severity in Never Smokers, Ex-Smokers, and Current Smokers With Axial Spondyloarthritis: Results From the Scotland Registry for Ankylosing Spondylitis. Jones GT, Ratz T, Dean LE, Macfarlane GJ, Atzeni F. Arthritis Care Res (Hoboken). 2017 Sep;69(9):1407-1413 (2017)
https://pubmed.ncbi.nlm.nih.gov/?term=atzeni+f+spondyloarthritis&format=pmid&sort=pubdate